BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
10.42
+0.53 (5.36%)
At close: Mar 6, 2026, 4:00 PM EST
10.62
+0.20 (1.92%)
After-hours: Mar 6, 2026, 7:33 PM EST

BBOT Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023
Period Ending
Dec '25 Dec '24 Dec '23
Selling, General & Admin
24.627.768.49
Research & Development
121.273.1156.29
Operating Expenses
145.8280.8664.77
Operating Income
-145.82-80.86-64.77
Interest & Investment Income
11.346.380.07
Other Non Operating Income (Expenses)
0.430.21-
Pretax Income
-134.04-74.28-64.7
Net Income
-134.04-74.28-64.7
Net Income to Common
-134.04-74.28-64.7
Shares Outstanding (Basic)
3100
Shares Outstanding (Diluted)
3100
Shares Change (YoY)
21360.65%16.36%-
EPS (Basic)
-4.30-511.80-518.73
EPS (Diluted)
-4.30-511.80-518.73
Free Cash Flow
-114.5-55.08-52.49
Free Cash Flow Per Share
-3.68-379.51-420.87
EBITDA
-145.54-80.66-64.68
D&A For EBITDA
0.280.210.09
EBIT
-145.82-80.86-64.77
Source: S&P Capital IQ. Standard template. Financial Sources.